positive, page-20

Positive quotes 2016.............V
Expert Comments:mce-anchor

	Column 1	Column 2
0	Katherine Genis, Edison Investment Research (3/24/16)"In September 2015 Mesoblast Ltd. announced Phase 2 trial results for MPC-150-IM, showing greatest cardioprotective effect in patients with advanced heart failure. Clinical data from two Phase 3 studies will support regulatory approval; interim analysis of the first trial is anticipated in Q2/16."
1		Jason Kolbert, Maxim Group (3/17/16)"The strength in Mesoblast Ltd.'s shares appears to be a result of an artificially depressed valuation triggered by the U.S. NASDAQ listing. Given the success in Japan and the multiple catalysts ahead, as well as other recent success in the competitive landscape of cell therapy, we believe the rebound in valuation is justified."
2	Henry McCusker, RegMed Investors (2/25/16)"A Mesoblast Ltd. licensee launched the first allogeneic cell therapy product in Japan for the treatment of acute graft-versus-host disease in children and adults. . .Temcell is the first allogeneic cell therapy to be fully approved in Japan. The Japanese government's National Health Insurance set reimbursement for Temcell at 868,680 yen (approximately $7,700) per bag of 72M cells."
3		Kevin DeGeeter, Ladenburg Thalmann (2/23/16)"Mesoblast Ltd. presented results from 241 patients enrolled onto Protocol 275, an expanded access study of remestemcel-L for steroid-refractory acute graft-versus-host disease. . .on net, the results give us increased confidence the ongoing Phase 3 study of remestemcel-L in 60 children will be positive. The company expects to present interim topline data in Q3/16 with complete data in H1/17."
4		Jason Kolbert, Maxim Group (2/22/16)"Mesoblast Ltd. announced results for MSC-100-IV that showed clinically meaningful responses and significantly increased survival in children with steroid-refractory acute graft-versus-host disease (aGVHD). . .key results in the 241 children with steroid-refractory aGVHD were: an overall response rate of 65% was seen at day 28 after treatment with MSC-100-IV, and a response rate of 81% was seen when MSC-100-IV was used as frontline therapy following steroid failure."
5	Jason Kolbert, Maxim Group (2/16/16)"Mesoblast Ltd.'s allogeneic cell therapy product, MPC-300 IV, is being evaluated in a double-blind, randomized, placebo-controlled, two-dose escalating trial in the U.S. . .the data look amazing in our view, especially when we consider that all the cell infusions were well tolerated with no cell-related adverse events. In other words we believe there is no risk but clearly activity."